EE279 Cost-Effectiveness Analysis of Biosimilars and Novel Biologics for Patients With Moderate-to-Severe Psoriasis
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.578
https://www.valueinhealthjournal.com/article/S1098-3015(24)00693-4/fulltext
Title :
EE279 Cost-Effectiveness Analysis of Biosimilars and Novel Biologics for Patients With Moderate-to-Severe Psoriasis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00693-4&doi=10.1016/j.jval.2024.03.578
First page :
Section Title :
Open access? :
No
Section Order :
10052